|
1
|
No authors listed. Standards of medical
care in diabetes - 2015: Summary of revisions. Diabetes Care.
38(Suppl 4)2015.
|
|
2
|
Sarabia V, Lam L, Burdett E, Leiter LA and
Klip A: Glucose-transport in human skeletal-muscle cells in
culture. Stimulation by insulin and metformin. J Clin Invest.
90:1386–1395. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hundal RS, Krssak M, Dufour S, Laurent D,
Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF,
Landau BR and Shulman GI: Mechanism by which metformin reduces
glucose production in type 2 diabetes. Diabetes. 49:2063–2069.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shaw RJ, Lamia KA, Vasquez D, Koo SH,
Bardeesy N, DePinho RA, Montminy M and Cantley LC: The kinase LKB1
mediates glucose homeostasis in liver and therapeutic effects of
metformin. Science. 310:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou GC, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kahn BB, Alquier T, Carling D and Hardie
DG: AMP-activated protein kinase: Ancient energy gauge provides
clues to modern understanding of metabolism. Cell Metab. 1:15–25.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hemminki A, Markie D, Tomlinson I,
Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M,
Höglund P, et al: A serine/threonine kinase gene defective in
Peutz-Jegheus syndrome. Nature. 391:184–187. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sanchez-Cespedes M: A role for LKB1 gene
in human cancer beyond the Peutz-Jeghers syndrome. Oncogene.
26:7825–7832. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ben Sahra I, Le Marchand-Brustel Y, Tanti
JF and Bost F: Metformin in cancer therapy: A new perspective for
an old antidiabetic drug? Mol Cancer Ther. 9:1092–1099. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Landman GW, Kleefstra N, van Hateren KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in Type 2 Diabetes - ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar :
|
|
11
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi WY, Xiao D, Wang L, Dong LH, Yan ZX,
Shen ZX, Chen SJ, Chen Y and Zhao WL: Therapeutic metformin/AMPK
activation blocked lymphoma cell growth via inhibition of mTOR
pathway and induction of autophagy. Cell Death Dis. 3:e2752012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tomic T, Botton T, Cerezo M, Robert G,
Luciano F, Puissant A, Gounon P, Allegra M, Bertolotto C, Bereder
JM, et al: Metformin inhibits melanoma development through
autophagy and apoptosis mechanisms. Cell Death Dis. 2:e1992011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ben Sahra I, Regazzetti C, Robert G,
Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF,
Giorgetti-Peraldi S and Bost F: Metformin, independent of AMPK,
induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer
Res. 71:4366–4372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mitsuhashi A, Kiyokawa T, Sato Y and Shozu
M: Effects of metformin on endometrial cancer cell growth in vivo:
A preoperative prospective trial. Cancer. 120:2986–2995. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Niraula S, Dowling RJ, Ennis M, Chang MC,
Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, et
al: Metformin in early breast cancer: A prospective window of
opportunity neoadjuvant study. Breast Cancer Res Treat.
135:821–830. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA-Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsumoto S, Iwakawa R, Takahashi K, Kohno
T, Nakanishi Y, Matsuno Y, Suzuki K, Nakamoto M, Shimizu E, Minna
JD and Yokota J: Prevalence and specificity of LKB1 genetic
alterations in lung cancers. Oncogene. 26:5911–5918. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sanchez-Cespedes M, Parrella P, Esteller
M, Nomoto S, Trink B, Engles JM, Westra WH, Herman JG and Sidransky
D: Inactivation of LKB1/STK11 is a common event in adenocarcinomas
of the lung. Cancer Res. 62:3659–3662. 2002.PubMed/NCBI
|
|
23
|
Carretero J, Medina PP, Pio R, Montuenga
LM and Sanchez-Cespedes M: Novel and natural knockout lung cancer
cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene.
23:4037–4040. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guertin DA and Sabatini DM: Defining the
role of mTOR in cancer. Cancer Cell. 12:9–22. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Duncan LJ and Seaton DA: The treatment of
diabetes mellitus with metformin. Br J Clin Pract. 16:129–132.
1962.PubMed/NCBI
|
|
26
|
Janjetovic K, Harhaji-Trajkovic L,
Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N,
Sumarac-Dumanovic M, Micic D and Trajkovic V: In vitro and in vivo
anti-melanoma action of metformin. Eur J Pharmacol. 668:373–382.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hardie DG and Alessi DR: LKB1 and AMPK and
the cancer-metabolism link-ten years after. BMC Biol. 11:362013.
View Article : Google Scholar
|
|
28
|
Rattan R, Giri S, Hartmann LC and Shridhar
V: Metformin attenuates ovarian cancer cell growth in an AMP-kinase
dispensable manner. J Cell Mol Med. 15:166–178. 2011. View Article : Google Scholar
|
|
29
|
Algire C, Amrein L, Bazile M, David S,
Zakikhani M and Pollak M: Diet and tumor LKB1 expression interact
to determine sensitivity to anti-neoplastic effects of metformin in
vivo. Oncogene. 30:1174–1182. 2011. View Article : Google Scholar
|
|
30
|
Waldman T, Zhang Y, Dillehay L, Yu J,
Kinzler K, Vogelstein B and Williams J: Cell-cycle arrest versus
cell death in cancer therapy. Nat Med. 3:1034–1036. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luo Q, Hu D, Hu S, Yan M, Sun Z and Chen
F: In vitro and in vivo anti-tumor effect of metformin as a novel
therapeutic agent in human oral squamous cell carcinoma. BMC
Cancer. 12:5172012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang LW, Li ZS, Zou DW, Jin ZD, Gao J and
Xu GM: Metformin induces apoptosis of pancreatic cancer cells.
World J Gastroenterol. 14:7192–7198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Conde E, Suarez-Gauthier A, García-García
E, Lopez-Rios F, Lopez-Encuentra A, García-Lujan R, Morente M,
Sanchez-Verde L and Sanchez-Cespedes M: Specific pattern of LKB1
and phospho-acetyl-CoA carboxylase protein immunostaining in human
normal tissues and lung carcinomas. Hum Pathol. 38:1351–1360. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Motoshima H, Goldstein BJ, Igata M and
Araki E: AMPK and cell proliferation-AMPK as a therapeutic target
for atherosclerosis and cancer. J Physiol. 574:63–71. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
El-Mir MY, Nogueira V, Fontaine E, Avéret
N, Rigoulet M and Leverve X: Dimethylbiguanide inhibits cell
respiration via an indirect effect targeted on the respiratory
chain complex I. J Biol Chem. 275:223–228. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Owen MR, Doran E and Halestrap AP:
Evidence that metformin exerts its anti-diabetic effects through
inhibition of complex 1 of the mitochondrial respiratory chain.
Biochem J. 348:607–614. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xie Z, Dong Y, Scholz R, Neumann D and Zou
MH: Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta
is required for metformin-enhanced activation of the AMP-activated
protein kinase in endothelial cells. Circulation. 117:952–962.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ouyang JY, Parakhia RA and Ochs RS:
Metformin activates AMP kinase through inhibition of AMP deaminase.
J Biol Chem. 286:1–11. 2011. View Article : Google Scholar :
|
|
39
|
Foretz M, Hébrard S, Leclerc J,
Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F and
Viollet B: Metformin inhibits hepatic gluconeogenesis in mice
independently of the LKB1/AMPK pathway via a decrease in hepatic
energy state. J Clin Invest. 120:2355–2369. 2010. View Article : Google Scholar : PubMed/NCBI
|
